Drug–gene and drug–drug interactions associated with tramadol and codeine therapy in the INGENIOUS trial

dc.contributor.authorFulton, Cathy R.
dc.contributor.authorZang, Yong
dc.contributor.authorDesta, Zeruesenay
dc.contributor.authorRosenman, Marc B.
dc.contributor.authorHolmes, Ann M.
dc.contributor.authorDecker, Brian S.
dc.contributor.authorZhang, Yifei
dc.contributor.authorCallaghan, John T.
dc.contributor.authorPratt, Victoria M.
dc.contributor.authorLevy, Kenneth D.
dc.contributor.authorGufford, Brandon T.
dc.contributor.authorDexter, Paul R.
dc.contributor.authorSkaar, Todd C.
dc.contributor.authorEadon, Michael T.
dc.contributor.departmentMedicine, School of Medicineen_US
dc.date.accessioned2020-06-24T16:59:08Z
dc.date.available2020-06-24T16:59:08Z
dc.date.issued2019-04
dc.description.abstractBackground: Tramadol and codeine are metabolized by CYP2D6 and are subject to drug-gene and drug-drug interactions. Methods: This interim analysis examined prescribing behavior and efficacy in 102 individuals prescribed tramadol or codeine while receiving pharmaco-genotyping as part of the INGENIOUS trial (NCT02297126). Results: Within 60 days of receiving tramadol or codeine, clinicians more frequently prescribed an alternative opioid in ultrarapid and poor metabolizers (odds ratio: 19.0; 95% CI: 2.8-160.4) as compared with normal or indeterminate metabolizers (p = 0.01). After adjusting the CYP2D6 activity score for drug-drug interactions, uncontrolled pain was reported more frequently in individuals with reduced CYP2D6 activity (odds ratio: 0.50; 95% CI: 0.25-0.94). Conclusion: Phenoconversion for drug-drug and drug-gene interactions is an important consideration in pharmacogenomic implementation; drug-drug interactions may obscure the potential benefits of genotyping.en_US
dc.eprint.versionFinal published versionen_US
dc.identifier.citationFulton, C. R., Zang, Y., Desta, Z., Rosenman, M. B., Holmes, A. M., Decker, B. S., Zhang, Y., T Callaghan, J., Pratt, V. M., Levy, K. D., Gufford, B. T., Dexter, P. R., Skaar, T. C., & Eadon, M. T. (2019). Drug-gene and drug-drug interactions associated with tramadol and codeine therapy in the INGENIOUS trial. Pharmacogenomics, 20(6), 397–408. https://doi.org/10.2217/pgs-2018-0205en_US
dc.identifier.urihttps://hdl.handle.net/1805/23075
dc.language.isoen_USen_US
dc.publisherFuture Medicineen_US
dc.relation.isversionof10.2217/pgs-2018-0205en_US
dc.relation.journalPharmacogenomicsen_US
dc.rightsPublisher Policyen_US
dc.sourcePMCen_US
dc.subjectAdverse side effectsen_US
dc.subjectCYP2D6en_US
dc.subjectIGNITEen_US
dc.subjectINGENIOUSen_US
dc.subjectPharmacogeneticsen_US
dc.subjectOpioidsen_US
dc.subjectPharmacogenomicsen_US
dc.subjectPhenoconversionen_US
dc.titleDrug–gene and drug–drug interactions associated with tramadol and codeine therapy in the INGENIOUS trialen_US
dc.typeArticleen_US
ul.alternative.fulltexthttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6562829/en_US
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
pgs-20-397.pdf
Size:
492.67 KB
Format:
Adobe Portable Document Format
Description:
Main article
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description: